Glycogen Synthase Kinase-3 Phosphorylates CdGAP at a Consensus ERK 1 Regulatory Site*

Eric Ian Danek 1, Joseph Tcherkezian 2, Ibtissem Triki, Mayya Meriane 1, and Nathalie Lamarche-Vane 4
From the Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec H3A 2B2, Canada

Rho GTPases regulate a multitude of cellular processes from cytoskeletal reorganization to gene transcription and are negatively regulated by GTPase-activating proteins (GAPs). Cdc42 GTPase-activating protein (CdGAP) is a ubiquitously expressed GAP for Rac1 and Cdc42. In this study, we set out to identify CdGAP-binding partners and, using a yeast two-hybrid approach, glycogen synthase kinase 3α (GSK-3α) was identified as a partner for CdGAP. GSK-3 exists in two isoforms, α and β, and is involved in regulating many cellular functions from insulin response to tumorigenesis. We show that GSK-3α and -β interact with CdGAP in mammalian cells. We also demonstrate that GSK-3 phosphorylates CdGAP both in vitro and in vivo on Thr-776, which we have previously shown to be an ERK 1/2 phosphorylation site involved in CdGAP regulation. We report that the mRNA and protein levels of CdGAP are increased upon serum stimulation and that GSK-3 activity is necessary for the up-regulation of the protein levels of CdGAP but not for the increase in mRNA. We conclude that GSK-3 is an important regulator of CdGAP and that regulation of CdGAP protein levels by serum presents a novel mechanism for cells to control Cdc42/Rac1 GTPase signaling pathways.

The Rho subfamily of small GTPases controls a wide variety of cellular functions. RhoA, Rac1, and Cdc42 are the best known members of this family, and they are most often associated with their roles as regulators of cytoskeleton remodeling and as key mediators of the activation of transcription of genes downstream of growth factor receptors (1). Much evidence exists linking Rho GTPases to transformation of cells; however, contrary to the Ras gene, activating mutations in Rho genes are not always associated with their roles as regulators of cytoskeleton remodeling and as key mediators of the activation of transcription of genes downstream of growth factor receptors (1). Much evidence exists linking Rho GTPases to transformation of cells; however, contrary to the Ras gene, activating mutations in Rho genes are rarely found in human cancers (2, 3). It seems instead that the expression of Rho GTPases and expression and function of regulators of the Rho subfamily of GTPases are altered during cellular transformation (2, 3).

Rho GTPases act in a cycle as molecular switches with an active GTP-bound form and an inactive GDP-bound form (1). The GTPase-activating proteins (GAPs) negatively regulate the GTPases by enhancing the hydrolysis of GTP to GDP (1). To date, ~70 human genes are predicted to encode for potential RhoGAP proteins (4), which is roughly triple the number of Rho GTPases (1). This lends weight to the notion that regulators like the RhoGAPs tightly control Rho GTPases and lend context-dependent specificity to their processes. Thus, the activity of RhoGAPs must be highly regulated in both spatial and temporal fashions. RhoGAPs are regulated at the protein level by a variety of mechanisms ranging from protein-protein interactions to phosphorylation, lipid interactions, and proteolytic degradation (5).

Cdc42 GTPase-activating protein (CdGAP) has been shown to regulate both Cdc42 and Rac1 in vitro and in vivo and exists in two main isoforms: a short form of 820 amino acids containing an N-terminal RhoGAP domain, a central region, and a C-terminal proline-rich region (PRD) (6, 7) and a long isoform comprising the entire short form with an additional C-terminal region extending to 1425 amino acids total (8). Recently, we demonstrated that CdGAP activity is negatively controlled by protein-protein interactions via the endocytic protein intersectin (6) and by phosphorylation within its PRD (8).

In this study, we used a yeast two-hybrid approach to look for binding partners for the PRD of CdGAP and found glycogen synthase kinase-3α (GSK-3α) as an interacting partner. GSK-3α and its closely related isoform GSK-3β are serine/threonine protein kinases initially identified as key enzymes in the regulation of glycogen metabolism by insulin and are now known to be implicated in many diverse cellular processes including tumorigenesis, cell survival, and developmental patterning (9, 10). We demonstrate that GSK-3β can also bind CdGAP. We further report that GSK-3 phosphorylates CdGAP in vivo under serum-starved conditions where GSK-3 is most active. GSK-3 phosphorylates CdGAP both in vitro and in vivo at Thr-776, which we have previously shown to be an ERK1/2 phosphorylation site involved in CdGAP regulation (8). We demonstrate that the mRNA and protein levels of CdGAP are up-regulated in response to serum in a transcriptionally mediated manner and that GSK-3 activity is critical in the up-regulation of protein levels but not mRNA levels.

* This work was supported by the Canadian Cancer Society through the National Cancer Institute of Canada. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Recipient of a Canada Graduate Scholarship administered by the Canadian Institutes of Health Research (CIHR).

2 Present address: Dept. of Cell Biology and Program in Neuroscience, Harvard Medical School, Boston, MA 02115.

3 Recipient of a Postdoctoral Fellowship Award from the CIHR.

4 The recipient of a CIHR New Investigator Award. To whom correspondence should be addressed: Dept. of Anatomy and Cell Biology, McGill University, 3640 University St., Montreal, QC H3A 2B2, Canada. Tel.: 514-398-1784; Fax: 514-398-5047; E-mail: nathalie.lamarche@mcgill.ca.

5 The abbreviations used are: GAP, GTPase-activating protein; CdGAP, Cdc42 GTPase-activating protein; CdGAP-I, CdGAP long isoform; CdGAP-s, CdGAP short isoform; PRD, proline-rich domain; GSK-3, glycogen synthase kinase 3; ActD, actinomycin D; DRB, 5,6-dichlorobenzimidazole-1-β-D-ribofuranoside; MBP, myelin basic protein; MOPS, 4-morpholinepropanesulfonic acid.
EXPERIMENTAL PROCEDURES

Reagents and Antibodies—Lithium chloride, AR-A014418, SB 415286, actinomycin D (ActD), and 5,6-dichlorobenzimidazole 1-β-d-ribofuranoside (DRB) were purchased from Sigma Canada, and sodium chloride was from Fisher. Anti-GSK-3α antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), anti-GSK-3β antibody was from Cell Signaling Technologies, anti-GSK3 (both α and β) antibody was from Upstate Biotechnology, Inc. (Lake Placid, NY), and anti-phospho-GSK-3 antibody, anti-phospho-Ser-641 glycogen synthase, and anti-glycogen synthase antibodies were from Cell Signaling Technologies. [32P]ATP (3,000 Ci/mmol) and [32P]orthophosphate (3,000 μCi/ml) were purchased from PerkinElmer Life Sciences. Recombinant GSK-3α and -β and phospho-glycogen synthase peptide were purchased from Upstate Biotechnology. Polyclonal anti-CdGAP antibodies were produced and purified as described previously (8, 11). Polyclonal antibodies against phospho-Thr-776 of CdGAP were produced and purified as described previously (8, 11). Polyclonal antibodies against phospho-GSK-3 antibody, anti-phospho-Ser-641 glycogen synthase, and anti-glycogen synthase antibodies were from Cell Signaling Technologies. [32P]orthophosphate (3,000 Ci/ml) were purchased from New England Nuclear. [32P]orthophosphate/ml, with or without treatment with the above-mentioned compounds for 1 h. Cells were then incubated for 2 h in phosphate-free medium supplemented with 0.5 mCi of [32P]orthophosphate/ml, with or without treatment with the above mentioned compounds. The cells were lysed, and CdGAP was immunoprecipitated using polyclonal anti-CdGAP antibodies (8) overnight at 4 °C. The samples were submitted to SDS-PAGE followed by transfer to nitrocellulose and then autoradiography and Western blotting against CdGAP.

In Vivo [32P]orthophosphate Labeling—NIH 3T3 cells were serum-starved overnight. The cells were either left untreated or were treated with 50 mM LiCl, 50 mM NaCl, or 0.1% Me2SO or with 100 μM SB 415286 or AR-A014418 for 1 h. This was followed by 1-h incubation in either phosphate-free medium or phosphate-free medium treated with the above-mentioned compounds for 1 h. Cells were then incubated for 2 h in phosphate-free medium supplemented with 0.5 mCi of [32P]orthophosphate/ml, with or without treatment with the above mentioned compounds. The cells were lysed, and CdGAP was immunoprecipitated and polyclonal anti-CdGAP antibodies (8) overnight at 4 °C. The samples were submitted to SDS-PAGE followed by transfer to nitrocellulose and then autoradiography and Western blotting against CdGAP.

In Vitro Kinase Assay and Phospho-Amino Acid Analysis—Hexahistidine fusion proteins—CdGAP-PRD or CdGAP-PRD-T776A were produced and purified as described previously (8). His-tagged CdGAP-PRD or CdGAP-PRD-T776A were incubated with 10 ng of active GSK-3α or GSK-3β (Upstate Biotechnology) in 8 mM MOPS, pH 7.0, 200 mM EDTA, 10 mM MgCl2, 100 μM ATP, and 10 μCi/ml [γ-32P]ATP for 10 min at 30 °C. The reaction was stopped by the addition of Laemmli buffer. The samples were submitted to SDS-PAGE followed by transfer to nitrocellulose and then autoradiography. A range of CdGAP-PRD concentrations from 18.2 nM to 9.32 μM were used to estimate the K_m value using the Lineweaver-Burk equation (14). Phospho-amino acid analysis was performed as described previously (8, 15).

Quantitative Reverse Transcription-PCR—NIH 3T3 cells were serum-starved overnight. The cells were either left
untreated or treated with 15% serum or with 15% serum with transcriptional or GSK-3 inhibitors for various times. Total RNA was extracted using a Qiagen RNeasy kit (Qiagen). mRNA was reverse-transcribed using enzymes from Invitrogen. The cDNA was then run in a quantitative real-time PCR reaction using a Roche Applied Science Lightcycler, Qiagen Quantitect Sybr green reagents, and CdGAP primers obtained from Gene-globe. 18S ribosomal subunit primers (a kind gift from Dr. Simon Wing, McGill University) were used as a loading control.

RESULTS

The PRD of CdGAP harbors five consensus SH3-binding motifs and is known to be necessary in the regulation of CdGAP activity (6). To identify target proteins that interact with CdGAP through this region of the protein, we used the PRD (amino acids 516–820) as bait in a yeast two-hybrid screen with a human brain cDNA library. GSK-3α was isolated as a positive clone growing on selective medium (Fig. 1A) and expressing β-galactosidase (Fig. 1B). To examine whether CdGAP interacts with both GSK-3α and GSK-3β in mammalian cells, Myc-tagged CdGAP-long (CdGAP-I), short (CdGAP-s), or PRD (CdGAP-PRD) were co-transfected with either pRK5myc vector or pRK5myc vector containing CdGAP-s, CdGAP-I, or CdGAP-PRD into HEK 293 cells. Anti-Myc immunoprecipitations (IP) were carried out followed by SDS-PAGE and transfer to nitrocellulose membrane. Western blots were performed against the Myc epitope tag and GSK-3α (A) or GSK-3β (B).
To investigate whether endogenous CdGAP phosphorylation is mediated by GSK-3, NIH 3T3 cells endogenously expressing the long isoform of CdGAP (CdGAP-L) were serum-starved overnight and were then left untreated or were treated with the GSK-3 inhibitors LiCl (9), SB 415286 (16), or AR-A014418 (17) for 1 h prior to incubation in phosphate-free medium supplemented with [32P]orthophosphate. As expected, GSK-3 activity was inhibited as indicated by Western blotting for phospho-Ser-641 of glycogen synthase, a known GSK-3 substrate (18) (Fig. 3B). Additionally, inhibition of GSK-3 by LiCl is indicated by the increase in phospho-serine 9 of GSK-3, a site whose phosphorylation is affected by LiCl but not the SB 415286 or AR-A014418 inhibitors (19). CdGAP-L was phosphorylated under serum-starved conditions where GSK-3 was active, as well as when sodium chloride and Me2SO were present as negative controls; however, its phosphorylation was significantly reduced by the three GSK-3 inhibitors (Fig. 3A). Therefore, these results show that CdGAP-L is in vivo phosphorylated by GSK-3 in NIH 3T3 cells.

We next tested whether GSK-3 phosphorylates CdGAP in vitro. Since we know that most of the phosphorylation of CdGAP is in the PRD (8), we performed in vitro kinase assays with recombinant His-tagged CdGAP-PRD incubated with activated GSK-3. As shown in Fig. 4A, both GSK-3α and GSK-3β were able to phosphorylate CdGAP-PRD in vitro. Using a range of CdGAP-PRD concentrations from 18.2 nM to 9.32 μM, we estimated a Kₘ value of 0.5 μM, showing that CdGAP-PRD is a very good substrate for GSK-3 (Fig. 4B). To determine which types of residues are phosphorylated by GSK-3, CdGAP-PRD phosphorylated in vitro by GSK-3α was used to perform a phospho-amino acid analysis. We found that CdGAP-PRD is mainly phosphorylated on threonine residues (Fig. 4C). The predicted consensus phosphorylation motif for GSK-3 consists of (S/T)XX(X/pS/pT) (20), in which a proline is a preferred residue adjacent to the phosphorylation site, and in most cases, a “primed” phosphorylation site is required at the 4 position prior to GSK-3 phosphorylation by substituting a charged residue at this site (21, 22). This is of particular interest

---

**Figure 4. CdGAP is phosphorylated in vitro on Thr-776 by GSK-3.** A, an in vitro kinase assay was performed using active GSK-3α (left panel), GSK-3β (middle panel), or no kinase (right panel) and either His-CdGAP-PRD or phospho-glycogen synthase (p-GS) followed by SDS-PAGE, transfer to nitrocellulose, and autoradiography (top panels) or Ponceau-S staining (bottom panels). B, an in vitro kinase assay was performed using recombinant GSK-3α and concentrations of His-CdGAP-PRD ranging from 18.2 nM to 9.32 μM. Incorporation of [32P]phosphate into CdGAP-PRD was determined by measuring the CPM. A Michaelis-Menten plot (i) was constructed by plotting V (V = CPM/minute) against [S] ([S] = concentration of CdGAP-PRD in moles/liter), and a Lineweaver-Burk plot (ii) was constructed by plotting 1/V against 1/[S]. C, in vitro phosphorylated His-CdGAP-PRD was hydrolyzed and submitted to phospho-amino acid analysis. Migration of phospho-amino acid standards is indicated with circles; Substances used are as follows: phospho-serine (P-S), phospho-threonine (P-T), and phosphotyrosine (P-Y). D, in vitro kinase assay using either GSK-3α or -β with His-CdGAP-PRD and His-CdGAP-PRD T776A. Samples were resolved by SDS-PAGE and were transferred to nitrocellulose followed by autoradiography and Western blotting (WB) using anti-His antibodies.
since GSK-3 efficiently phosphorylates CdGAP-PRD in vitro, whereas targets of GSK-3 that need priming generally make poor in vitro substrates of GSK-3, indicating that it may not need to be primed. CdGAP contains one atypical motif, within the proline-rich domain, TPE

We mutated Thr-776 to alanine and determined by in vitro kinase assays that its phosphorylation by GSK-3α and β was significantly reduced when compared with wild-type CdGAP-PRD (Fig. 4D). Interestingly, we have previously demonstrated that Thr-776 is a target site of ERK1/2 and acts as an important regulatory site of CdGAP activity in vivo (8).

We then developed a polyclonal antibody against CdGAP phospho-Thr-776. This antibody was able by Western blotting to recognize Myc-tagged CdGAP-s protein overexpressed in COS-7 fibroblasts but was unable to recognize both Myc-tagged CdGAP-s T776A and recombinant CdGAP-PRD expressed in Escherichia coli (data not shown). When Myc-tagged CdGAP-s was expressed in serum-starved NIH 3T3 cells, we found that CdGAP-s was phosphorylated on Thr-776 (Fig. 5). However, when these cells were incubated with LiCl for 5 h, the level of CdGAP-s with phosphorylated Thr-776 was markedly decreased relative to both serum-starved conditions, as well as cells that were incubated with NaCl for 5 h (Fig. 5A and B). Likewise, when cells were incubated with the GSK-3 inhibitor SB 415286 (16) for 5 h, the level of phospho-Thr-776 CdGAP-s was markedly decreased relative to both serum-starved conditions and cells that were incubated instead with Me₃SO (Fig. 5A and B). To examine whether Thr-776 of endogenous CdGAP is phosphorylated in vivo by GSK-3, U2OS osteosarcoma cells endogenously expressing the short isoform of CdGAP (23) were serum-starved overnight and then left untreated or were treated with the GSK-3 inhibitors SB 415286 or AR-A014418. We found that CdGAP-s was phosphorylated on Thr-776 under serum-starved conditions; however, CdGAP-s from cells that were incubated with the GSK-3 inhibitors showed a dramatic decrease in phosphorylation at this site (Fig. 5C). As expected, the decrease in the levels of phospho-Ser-641 glycogen synthase relative to total glycogen synthase confirmed that GSK-3 activity was inhibited (Fig. 5C). Altogether, these results indicate that GSK-3 phosphorylates in vivo the residue Thr-776 of CdGAP-s.

GSK-3 regulates a great deal of cellular functions, including gene expression and protein stability (10). To determine whether GSK-3 affects CdGAP protein levels, we first examined the levels of endogenous CdGAP-I proteins in subconfluent NIH 3T3 fibroblasts stimulated with serum for various periods of time. Interestingly, we observed that CdGAP-I protein levels were significantly augmented in response to serum (Fig. 6, A and B). This induction occurred as early as 1 h after stim-

**FIGURE 5. CdGAP is phosphorylated in vivo on Thr-776 by GSK-3.** A, NIH 3T3 cells transfected with empty vector or CdGAP-s were serum-starved overnight and were either left untreated or treated with 50 mM NaCl, 50 mM LiCl, 0.1% Me₃SO (DMSO), or 100 μM SB 415286 for 5 h. Protein lysates were subjected to SDS-PAGE followed by Western blotting against CdGAP phospho-Thr-776 (top panel). The membrane was stripped and reprobed with anti-CdGAP antibodies (bottom panel). B, quantitative analysis of A representing standard errors of the mean relative to three independent experiments.

GSK-3 Regulates CdGAP
ulation and showed a 3.7-fold increase in CdGAP protein levels after 5 h of serum stimulation (Fig. 6B). It has been reported that GSK-3 is only transiently inhibited by growth factors such as epidermal growth factor and FGF-1, with GSK-3 regaining activity in as little as 20 min after stimulation (24, 25). Indeed, after 5 h of stimulation with serum, the levels of total GSK-3 were unchanged, and inactive GSK-3 phosphorylated on Ser-9 was barely detectable (Fig. 6C, lanes 1 and 2). Under these conditions, we found that inhibition of GSK-3 by LiCl did not alter the levels of CdGAP in serum-starved cells (Fig. 6C, compare lanes 2 and 6, and 6E); however, when GSK-3 activity was inhibited in cells stimulated with serum, the increase in CdGAP protein levels was blocked (Fig. 6C, compare lanes 1 and 5, and 6E). NaCl was used as a negative control and had a slight effect on the levels of CdGAP in either serum-stimulated or serum-starved cells (Fig. 6C, compare lanes 3 and 4 with lanes 1 and 2, and 6E). Consistent with the results obtained with LiCl inhibition of GSK-3, we found that both AR-A014418 and SB 415286 inhibited the increase in the levels of CdGAP proteins in response to serum (Fig. 6, D and E). Thus, these findings demonstrate that GSK-3 activity is necessary to regulate the levels of CdGAP proteins in response to serum.

To address whether the change in the levels of CdGAP protein resulted from a change in mRNA levels, we determined the mRNA levels of CdGAP in serum-stimulated NIH 3T3 fibroblasts by quantitative reverse transcription-PCR. As shown in Fig. 7A, the mRNA levels of CdGAP-l increased over a period of 30 min to 5 h of serum stimulation, with a peak at 4 h (Fig. 7A). To determine whether this increase in CdGAP mRNA was mediated transcriptionally, serum-starved NIH 3T3 cells were pretreated with either ActD or DRB prior to serum stimulation. These compounds inhibit transcription of RNA (26). In serum-starved cells treated with ActD or DRB, the mRNA levels of CdGAP appeared to be reduced when compared with control cells (Fig. 7B, lanes 5 and 7). Following serum stimulation, a slight increase in the levels of CdGAP mRNA was observed in the presence of ActD, whereas there was no increase in CdGAP mRNA levels in DRB-treated cells (Fig. 7B, lanes 6 and 8). This demonstrates that transcription is involved in the process of up-regulation of mRNA levels; however, it does not exclude the possibility that there may be some alternative mechanisms, such as mRNA stabilization. To determine whether GSK-3 affects the levels of CdGAP mRNA, serum-starved cells were treated with LiCl or NaCl while being stimulated with serum. As shown in Fig. 7C, the mRNA levels of CdGAP showed a 4-fold increase following a 5-h stimulation with serum, similar

indicated times. Protein lysates were subjected to SDS-PAGE followed by Western blotting against CdGAP and β-actin. B, quantitative analysis of A representing the amounts of CdGAP protein relative to those in serum-starved conditions. Error bars represent standard errors of the mean relative to three independent experiments. C, NIH 3T3 cells were serum-starved overnight and were left unstimulated or were stimulated for 5 h with 15% serum in the presence or absence of 50 mM NaCl or 50 mM LiCl. Protein lysates were subjected to SDS-PAGE followed by Western blotting against CdGAP, phospho-Ser-9 GSK-3β, GSK-3α and β, and β-actin. D, NIH 3T3 cells were serum-starved overnight and were left unstimulated or were stimulated for 5 h with 15% serum in the presence or absence of 0.1% Me2SO (DMSO) or 100 μM AR-A014418 or 100 μM SB 415286. Protein lysates were subjected to SDS-PAGE followed by Western blotting against CdGAP and β-actin. E, quantitative analysis of C and D was performed as above.
to the increase in protein levels (Fig. 6B). Interestingly, the LiCl GSK-3 inhibitor did not inhibit the increase in CdGAP mRNA levels induced by serum (Fig. 7C). Taken together, these findings indicate that CdGAP expression is up-regulated by serum and that GSK-3 activity is necessary to regulate the levels of CdGAP proteins post-transcriptionally.

**DISCUSSION**

To gain insight into the cellular function of CdGAP, we undertook a search for binding partners for the proline-rich domain of CdGAP, a region known to be important for the regulation of CdGAP activity (6). Through a yeast-two hybrid screen, we identified GSK-3β/H9251 as a binding partner for CdGAP-PRD and then determined that both GSK-3α and GSK-3β are able to interact with the short and long isoforms of CdGAP in mammalian cells. This, coupled with our knowledge of CdGAP phosphorylation within the PRD, led us to examine whether CdGAP is a physiological substrate for GSK-3. We found that inhibiting GSK-3 activity greatly attenuated the phosphorylation of endogenous CdGAP in both NIH 3T3 (Fig. 3) and Swiss 3T3 fibroblasts (data not shown). Subsequent analysis in vitro led us to discover that GSK-3 can phosphorylate CdGAP on Thr-776 within the proline-rich domain of CdGAP. Using a polyclonal antibody that recognized the phosphorylated residue Thr-776 of CdGAP, we demonstrated that this residue is an in vivo target site of GSK-3 in both NIH 3T3 cells and U2OS osteosarcoma cells. The identification of Thr-776 as a GSK-3 phosphorylation site is of great interest for at least two reasons. First, this site is an atypical GSK-3 phosphorylation site. The motif 776TPLE780 does not contain the usual +4 priming phospho-serine or phospho-threonine site that is typical for many GSK-3 substrates (21). Instead, it contains a negatively charged glutamic acid residue that can mimic the priming phosphorylation event required for the subsequent phosphorylation by GSK-3 (22). This may in part explain why GSK-3 efficiently phosphorylates recombinant CdGAP-PRD in vitro as it would not require this substrate to be primed by another kinase. Of note, however, is that amino acid substitution of Thr-776 to alanine did not completely eliminate GSK-3 phosphorylation of CdGAP in vitro, suggesting that other residues are phosphorylated by GSK-3. Second is the fact that this residue is an ERK 1 phosphorylation site important in the negative regulation of the GAP activity of CdGAP (8). Although there are not many examples of substrate sites that function for both ERK and GSK-3, it has been reported that the transcription factor CCAAT/enhancer binding protein β, and myelin basic protein (MBP) are phosphorylated at a consensus ERK/GSK-3 site (27, 28). In the case of CCAAT/enhancer binding protein β, it appears that its phosphorylation at a GSK-3/ERK consensus site is required for the induction of adiponectin gene expression during differentiation of mouse fibroblasts into adipocytes (27). For MBP, it is unclear what is the role of the consensus ERK/GSK-3 phosphorylation site, but this site is thought to play a role in changing the conformation of the protein, leading to changes in the interaction of MBP with the lipid bilayer in brain myelin (28). In the present study, our findings strongly suggest that phosphorylation of Thr-776 in the proline-rich domain of CdGAP is a consensus ERK-1/GSK-3 site required for regulation of CdGAP activity.

**FIGURE 7.** CdGAP mRNA levels are up-regulated by serum. A, NIH 3T3 cells were serum-starved overnight and were left unstimulated (t = 0) or were stimulated with 15% serum for the indicated times. Total RNA was extracted and submitted to reverse transcription followed by quantitative PCR to measure amounts of CdGAP and 18 S ribosomal subunit mRNAs. Quantitative analysis represents the amounts of CdGAP mRNA relative to those in serum-starved conditions. Error bars represent standard errors of the mean relative to at least three independent experiments. B, NIH 3T3 cells were serum-starved overnight and were then incubated with 0.1% DMSO (lanes 3 and 4), 10 μg/ml ActD (lanes 5 and 6), or 100 μM DRB (lanes 7 and 8) for 1 h before stimulation with 15% serum or 15% serum with Me2SO, ActD, or DRB. Quantitative analysis of CdGAP mRNA levels was done as above. C, NIH 3T3 cells were serum-starved overnight and were left unstimulated or were stimulated for 5 h with 15% serum in the presence or absence of 50 mM NaCl or LiCl. Quantitative analysis of CdGAP mRNA levels was done as above.
for a tight regulation of CdGAP activity under different cellular conditions.

This study also demonstrates that the cellular protein levels of CdGAP are serum-responsive. Five hours after stimulation with serum, the protein levels of CdGAP within the cells are elevated, and we have shown that this is concomitant with an increase in the amount of CdGAP mRNA. The inhibition of CdGAP mRNA increase by ActD or DRB suggests that this process is transcriptionally mediated; however, it does not rule out the possibility that there may also be other mechanisms such as stabilization of the mRNA that contribute to this process as well. Interestingly, we found that GSK-3 activity is required for the serum-dependent increase in the cellular protein levels of CdGAP but not the mRNA levels. Thus, these findings indicate that GSK-3 is acting post-transcriptionally to regulate the protein levels of CdGAP. It remains to be determined whether GSK-3 stimulates CdGAP protein synthesis or regulates its stability. Although more studies have reported the converse situation, where GSK-3 phosphorylation leads to protein instability, there are a few examples of proteins being stabilized after phosphorylation by GSK-3, namely the retinoblastoma-related pocket protein RBL2/p130 (29), the nuclear receptor Rev-erb (30), and axin, a component of the circadian clock (30), and in axin, a component of the ternary complex including β-catenin and APC (31).

As reported earlier by many studies, RhoGAPs are regulated post-translationally via various molecular mechanisms such as lipid interaction (32), protein-protein interaction (6), phosphorylation (8, 33), and proteolytic degradation (34). Clearly, CdGAP utilizes at least two of these mechanisms of regulation, including phosphorylation (8) and protein-protein interactions (6) to control its GAP activity. Here, we report for the first time the regulation of a RhoGAP protein at the transcriptional level in response to serum. The induction in mRNA levels occurred early (1 h) and peaked at 4 h, suggesting that CdGAP expression may represent a novel mitogen-inducible early gene (35). Future studies will be required to determine the molecular pathways necessary to activate CdGAP gene expression and their consequences on cell proliferation, migration, and survival.

In conclusion, we have identified CdGAP as a novel GSK-3 substrate, and stimulation of the cellular protein and mRNA levels of CdGAP by serum provides a novel mechanism to control Cdc42/Rac1 GTPase signaling pathways.

Acknowledgments—We are grateful to Nathalie Bedard for advice on quantitative reverse transcription-PCR and to Dr. John F. Presley for critical reading of this manuscript.

REFERENCES
1. Jaffe, A. B., and Hall, A. (2005) Annu. Rev. Cell Dev. Biol. 21, 247–269
2. Benitah, S. A., Valeron, P. F., van Aelst, L., Marshall, C. J., and Lacal, J. C. (2004) Biochim. Biophys. Acta 1705, 121–132
3. Gomez del Pulgar, T., Benitah, S. A., Valeron, P. F., Espina, C., and Lacal, J. C. (2005) BioEssays 27, 602–613
4. Bernards, A. (2003) Biochim. Biophys. Acta 1603, 47–82
5. Bernards, A., and Settleman, J. (2004) Trends Cell Biol. 14, 377–385
6. Jenna, S., Hussain, N. K., Danek, E. I., Triki, I., Wasiak, S., McPherson, P. S., and Larmarche-Vane, N. (2002) J. Biol. Chem. 277, 6366–6373
7. Larmarche-Vane, N., and Hall, A. (1998) J. Biol. Chem. 273, 29172–29177
8. Tcherkezian, J., Danek, E. I., Jenna, S., Triki, I., and Larmarche-Vane, N. (2005) Mol. Cell. Biol. 25, 6314–6329
9. Ali, A., Hoflich, K. P., and Woodgett, J. R. (2001) Chem. Rev. 101, 2527–2540
10. Doble, B. W., and Woodgett, J. R. (2003) J. Cell Sci. 116, 1175–1186
11. Tcherkezian, J., Triki, I., Stenne, R., Danek, E. I., and Larmarche-Vane, N. (2006) Biol. Cell 98, 445–456
12. Driessens, M. H., Hu, H., Nobes, C. D., Self, A., Jordens, I., Goodman, C. S., and Hall, A. (2001) Curr. Biol. 11, 339–344
13. Aspenstrom, P., and Olson, M. F. (1995) Methods Enzymol. 256, 228–241
14. Stryer, L. (1988) Biochemistry, 3rd Ed., pp. 187–191, W.H. Freeman and Co., New York, NY
15. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Methods Enzymol. 201, 110–149
16. Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Ruxbee Cox, L., Mills, D., Brown, M. J., Haigh, D., Ward, R. W., Smith, D. G., Murray, K. J., Reith, A. D., and Holder, J. C. (2000) Chem Biol 7, 793–803
17. Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormo, M., Nilsson, Y., Radesater, A. C., Jerning, E., Markgren, P. O., Borgger, T., Nylof, M., Gimenez-Cassina, A., Hernandez, F., Lucas, J. J., Diaz-Nido, J., and Avila, J. (2003) J. Biol. Chem. 278, 45937–45945
18. Picton, C., Woodgett, J., Hemmings, B., and Cohen, P. (1982) FEBS Lett. 150, 191–196
19. Lochhead, P. A., Coghlan, M., Rice, S. Q., and Sutherland, C. (2001) Diabetes 50, 937–946
20. Harwood, A. J. (2001) Cell 105, 821–824
21. Eldar-Finkelman, H. (2002) Trends Mol. Med. 8, 126–132
22. Trivedi, N., Marsh, P., Goold, R. G., Wood-Kaczmar, A., and Gordon-Weeks, P. R. (2005) J. Cell Sci. 118, 993–1005
23. Lalonde, D. P., Gubringer, M., Larmarche-Vane, N., and Turner, C. E. (2006) Curr. Biol. 16, 1375–1385
24. Eldar-Finkelman, H., Segel, R., Vanhendeede, J. R., and Krebs, E. G. (1995) J. Biol. Chem. 270, 987–990
25. Hashimoto, M., Sagara, Y., Langford, D., Everall, I. P., Mallory, M., Everson, A., Digicayilloglu, M., and Masliah, E. (2002) J. Biol. Chem. 277, 32985–32991
26. Ljungman, M., Zhang, F., Chen, F., Rainbow, A. J., and McKay, B. C. (1999) Oncogene 18, 583–592
27. Park, B. H., Qiang, L., and Farmer, S. R. (2004) Mol. Cell Biol. 24, 8671–8680
28. Yu, J. S., and Yang, S. D. (1994) J. Neurochem. 62, 1596–1603
29. Linovitch, L., Roesler, M., and DeCaprio, J. A. (2004) Mol. Cell. Biol. 24, 8970–8980
30. Yin, L., Wang, J., and Lazar, M. A. (2006) Science 311, 1002–1005
31. Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S., and Kikuchi, A. (1999) J. Biol. Chem. 274, 10681–10684
32. Ligeti, E., and Settleman, J. (2006) Methods Enzymol. 406, 104–117
33. Minoshima, Y., Kawashima, T., Hirose, K., Tonozuka, Y., Kawai, A., Bao, Y. C., Deng, X., Tatsuka, M., Narumiya, S., May, W. S., Jr., Nosaka, T., Semba, K., Inoue, T., Satoh, T., Inagaki, M., and Kitamura, T. (2003) Dev. Cell 4, 549–560
34. Su, L., Agati, J. M., and Parsons, S. J. (2003) J. Cell Biol. 163, 571–582
35. Herschman, H. R. (1991) Annu. Rev. Biochem. 60, 281–319